title: Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
abstract: Combination adjuvant therapy with intravenous dimethyl triazeno imidazole carboxamide (DTIC), 1-[4-amino-2-methyl-5-pyrimidinyl]-methyl-3-[2-chloroethyl]-3-nitrosoure a hydrochloride (ACNU) and vincristine (VCR) and local injection of interferon-beta (IFN-beta) (DAV + IFN-beta therapy) has been widely applied to treat malignant melanoma, and its therapeutic effect is accepted in Japan. Natural killer (NK) activity, CD4+ and CD8+ T cell counts, CD4/CD8 ratio, and white blood cell counts were analyzed before and after DAV + IFN-beta therapy in order to validate its efficacy. After DAV + IFN-beta therapy, the CD4/CD8 ratio was elevated; however, numbers of both CD4+ and CD8+ T cells and NK activity were consecutively depressed. Peripheral lymphocytes were also decreased, possibly by myelosuppression due to the DAV therapy. The posttreatment suppression of NK activity appeared in spite of the administration of IFN-beta. It is suggested that a more effective adjuvant immunomodulator should be introduced to improve the therapeutic effect of the combination adjuvant chemotherapy in malignant melanoma.
authors.affiliation: Department of Dermatology, School of Medicine, Tokyo Medical and Dental University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Umeda
authors.forename: K
authors.initials: K
authors.lastname: Aoki
authors.forename: A
authors.initials: A
authors.lastname: Yokoyama
authors.forename: H
authors.initials: H
authors.lastname: Ohara
authors.forename: O
authors.initials: O
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Nishioka
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D016899:Interferon-beta / Q000008:administration & dosage*; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology*; D008875:Middle Aged; D015376:Nimustine / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D018709:Statistics, Nonparametric; D013601:T-Lymphocytes / Q000187:drug effects; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D015376:Nimustine; D014750:Vincristine; D016899:Interferon-beta; D003606:Dacarbazine